Management of fertility preservation in young breast cancer patients in a large breast cancer centre

Lawrenz, Barbara; Neunhoeffer, E.; Henes, Melanie; Lessmann-Bechle, S; Krämer, B.; Fehm, Tanja

doi:10.1007/s00404-010-1523-0

Cited by 14 publications

(6 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two articles by the same author described one patient who ovulated during but not prior to stimulation and were therefore excluded [17,18]. Five studies did not differentiate luteal from follicular phase starts [9,[19][20][21][22]. Three studies did not report original data [23][24][25].…”

Section: Systematic Reviewmentioning

confidence: 99%

Ovarian stimulation in the luteal phase: systematic review and meta-analysis

Boots

Meister

Cooper

et al. 2016

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose The purpose of this study was to evaluate whether outcomes are different if controlled ovarian stimulation (COS) is started in the luteal phase rather than the follicular phase. Methods A systematic review and meta-analysis was performed. Sixteen studies were included in the qualitative analysis, and eight studies with a total of 338 women were included in the quantitative analysis. Results Cycles initiated in the luteal phase were slightly longer (WMD 1.1 days, 95 % CI 0.39-1.9) and utilized more total gonadotropins (WMD 817 IU, 95 % CI 489-1144). However, no differences were noted in peak estradiol levels (WMD −411 pg/ml, 95 % CI −906-84.7) or in the total number of oocytes retrieved (WMD 0.52 oocytes, 95 % CI −0.74-1.7). There were slightly more mature oocytes retrieved in the luteal phase (WMD 0.77 oocytes, 95 % CI 0.21-1.3), and fertilization rates were significantly higher (WMD 10 %, 95 % CI 0.03-0.18). While only three studies reported pregnancy outcomes, no difference was noted in the FET pregnancy rates after COS in the luteal versus follicular phase (RR 0.95, 95 % CI 0.56-1.7).A post hoc power analysis revealed that a sample of this size was sufficient to detect a clinically meaningful difference of 2 oocytes retrieved with 93 % power.Conclusion Although initiating COS in the luteal phase requires a longer stimulation and a higher dose of total gonadotropin, these differences are not clinically significant. Furthermore, COS initiated in the luteal phase does not compromise the quantity or quality of oocytes retrieved compared to outcomes of traditional stimulation in the follicular phase.

show abstract

Section: Systematic Reviewmentioning

confidence: 99%

Ovarian stimulation in the luteal phase: systematic review and meta-analysis

Boots

Meister

Cooper

et al. 2016

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…Certaines é quipes proposent la congé lation ovarienne aux patientes cé libataires en lieu et place de la congé lation ovocytaire ou aux patientes pour lesquelles la stimulation ovarienne n'est pas ré alisable pour des problè mes de dé lais, en cas de chimiothé rapie né oadjuvante ou pour les patientes RH+. C'est le cas du groupe fertiPROTEKT (www.fertiprotekt.com) [13].…”

Section: Cryopre´servation Ovarienneunclassified

Congélation d’embryons ou d’ovocytes avant chimiothérapie pour cancer du sein

Decanter¹,

Gligorov²

2011

Gynécologie Obstétrique & Fertilité

View full text Add to dashboard Cite

“…A longitudinal study (which admittedly only included 13 women under the age of 40 years) found that the biggest regret concerning decisions made about treatment was that the possibility of performing fertility-preservation treatment before the start of chemotherapy was not made use of [16]. Data collected from counseling of breast cancer patients on fertility-preservation methods prior Fertility conservation in breast cancer patients -Review to chemotherapy have shown that more than 60% of all counseled patients under the age of 40 years decided to undergo treatment with one or more fertility-preservation methods [17].…”

Section: Counseling Of Young Patients Prior To Chemotherapymentioning

confidence: 99%

Fertility Conservation in Breast Cancer Patients

Lawrenz

Henes

Neunhoeffer

et al. 2011

Womens Health (Lond Engl)

Self Cite

View full text Add to dashboard Cite

Breast cancer is the most common malignant tumor in women. Increasing survival rates after breast cancer, new reproductive techniques and growing interest regarding the quality of life after cancer have brought the possibilities of fertility-preserving treatment to the center of attention of oncologists and affected patients. Many of these women suffer from infertility and premature menopause as a result of chemotherapy. Several measures, for example gonadotropin-releasing hormone analogs, hormonal stimulation to cryopreserve oocytes, ovarian tissue cryoconservation or a combination of the methods, can be undertaken depending on the hormone receptor status of the tumor, and the patient's age and partner status. Embryo cryopreservation is currently the most promising fertility preservation option. Early counseling on fertility-preserving strategies is of utmost importance, so that the fertility-preserving method can be integrated into the oncologic therapy regime.

show abstract

Management of fertility preservation in young breast cancer patients in a large breast cancer centre

Abstract: The preservation of ovarian function and fertility are of great importance to young breast cancer patients. Counselling on fertility-preserving strategies is therefore critical in these patients and should be routinely performed.

Cited by 14 publications

References 21 publications

Ovarian stimulation in the luteal phase: systematic review and meta-analysis

Ovarian stimulation in the luteal phase: systematic review and meta-analysis

Congélation d’embryons ou d’ovocytes avant chimiothérapie pour cancer du sein

Fertility Conservation in Breast Cancer Patients

Contact Info

Product

Resources

About